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OBJECTIVE — Elevated lipopolysaccharide-binding protein (LBP), a marker of subclinical en-
dotoxemia, may be involved in the pathogenesis of obesity and metabolic risk. We aimed to inves-
tigate the association between plasma LBP and metabolic disorders in apparently healthy Chinese.
RESEARCH DESIGN AND METHODS — A population-based study including 559
overweight/obese (BMI 24.0 kg/m
2) and 500 normal-weight (18.0  BMI 24.0 kg/m
2)
subjects aged 35–54 years was conducted in Shanghai, China. Fasting plasma glucose, lipid
proﬁle, LBP, high-sensitivity C-reactive protein, interleukin-6, high-molecular-weight (HMW)
adiponectin, leptin, hepatic enzymes, and body composition were measured. Metabolic syn-
drome was deﬁned by the updated National Cholesterol Education Program Adult Treatment
Panel III criterion for Asian Americans.
RESULTS — LBPlevelsweresigniﬁcantlyhigherinoverweight/obeseindividualsthaninnormal-
weightindividuals(geometricmean27.6[95%CI25.2–30.3]vs.10.0[9.1–11.1]g/ml;P0.001).
After multiple adjustments including BMI, the odds ratios were 3.54 (95% CI 2.05–6.09) and 5.53
(95% CI 2.64–11.59) for metabolic syndrome and type 2 diabetes, respectively, comparing the
highestwiththelowestLBPquartile.Furtheradjustmentsforinﬂammatorymarkersalmostabolished
the signiﬁcant association of LBP with metabolic syndrome but not that with type 2 diabetes, and
controlling for adipokines and hepatic enzymes did not substantially alter the results.
CONCLUSIONS — Elevated circulating LBP was associated with obesity, metabolic syn-
drome, and type 2 diabetes in apparently healthy Chinese. These ﬁndings suggested a role of
lipopolysaccharide via initiation of innate immune mechanism(s) in metabolic disorders. Pro-
spective studies are needed to conﬁrm these results.
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O
besity, a major risk factor for meta-
bolic disorders, is reaching epi-
demic proportions worldwide with
1.6 billion overweight/obese adults in
2005 (1). An unhealthy diet and lifestyle-
associated obesogenic environment,
along with genetic predisposition, are the
main recognized drivers of the global ep-
idemic of obesity and associated meta-
bolic disorders. However, increasing
evidence supports the fact that chronic
low-grade inﬂammation is one of the key
mechanisms underlying the pathogenesis
ofobesity-relatedmetabolicdisorders(2).
However, the agents responsible for initi-
ating and sustaining this low-grade in-
ﬂammatory signal have yet to be
identiﬁed.
A link between chronic infection and
atherosclerosis has been postulated, in
which lipopolysaccharide (LPS) derived
from various Gram-negative bacteria
mightplayapivotalrole(3).Animalstud-
ies (4,5) and human evidence (6) sug-
gested that subclinical endotoxemia,
indicated by low to moderately elevated
LPS, may be involved in the pathogenesis
of metabolic disorders. Lowering LPS
concentrations through antibiotic (4) or
rosiglitazone therapy (6) could improve
metabolic outcomes. LPS is a potential
factor in triggering the innate immune re-
sponse and modulating the inﬂammatory
cascade via stimulation of the nuclear fac-
tor-B pathway and transcription of
proinﬂammatory genes (7). However, the
short half-life of LPS (8) and the difﬁculty
of removing interference in blood (9)
limittheutilityofLPStestinginclinicalor
research settings.
Lipopolysaccharide-binding protein
(LBP), an acute-phase protein synthe-
sized in liver, initiates recognition and
monomerization of LPS and ampliﬁes
host responses to LPS (10). Having a rel-
atively long half-life, LBP delivers LPS to
membrane and soluble forms of CD14
and consequently interacts with Toll-like
receptor 4, triggering a downstream sig-
naling cascade that leads to the upregula-
tionofproinﬂammatorycytokines(7,10).
Therefore, the presence of LBP could re-
ﬂect an “effective” LPS level and innate
immune response triggered by LPS
(11,12).
Limited data have suggested that ele-
vatedLBPlevelswereobservedinpatients
with nonalcoholic fatty liver disease (11)
and were associated with unfavorable ef-
fects on metabolic traits in glucose-
intolerant men (13) or with the increased
prevalence of coronary artery disease
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related metabolic disorders has not been
explored. Therefore, we aimed to investi-
gate whether plasma LBP concentrations
were associated with metabolic disorders
such as metabolic syndrome, insulin re-
sistance, and type 2 diabetes and also to
what extent the associations were ex-
plained by adiposity, adipokines, hepatic
enzymes,andinﬂammationinapparently
healthy Chinese.
RESEARCH DESIGN AND
METHODS— The Gut Microbiota
and Obesity Study was a population-
basedcase-controlstudyamongnoninsti-
tutionalized residents aged 35–54 years
in Shanghai, China. This study investi-
gatedtheeffectsofgutmicrobiotaanden-
vironmental factors on obesity and
related metabolic disorders. Two urban
districts(LuwanandZhabei)werechosen
to represent people with high and low so-
cioeconomic status in urban Shanghai.
Participants were enrolled through their
response to an advertisement. The ﬁeld-
work was conducted simultaneously in
both districts from November 2007
through January 2008. Five hundred
pairs of age- and sex-matched subjects
(overweight/obesity) and control subjects
(normal-weight) were planned to be re-
cruited. This sample size presumably
couldprovide80%powertodetecta25%
difference in gut microbiota composition
betweengroups(14).Overweight/obesity
and normal weight were deﬁned as BMI
24.0 kg/m
2 and 18.0  BMI 24.0 kg/
m
2, respectively, which was modiﬁed
from the recommendation by the Work-
ing Group on Obesity in China (15).
Eligible candidates were adult resi-
dents who have lived in Shanghai for at
least 10 years. Exclusion criteria included
1) diarrhea for 3 consecutive days within
the previous 3 months, 2) heavy alcohol
consumption(40g/dayethanolformen
and 20 g/day for women), 3) diagnosed
diabetes,takingoralantidiabeticagentsor
insulin, cancer, coronary heart disease,
myocardial infarction, stroke, or severe
kidney or liver diseases, 4) infectious dis-
eases including tuberculosis, AIDS, and
hepatitis, 5) severe psychological disor-
ders or physical disabilities, 6) antibiotics
used for 3 consecutive days within the
previous 3 months, 7) gastrointestinal
surgery within 1 year, or 8) pregnancy or
lactation in women. The protocol was ap-
proved by the Institutional Review Board
of the Institute for Nutritional Sciences
and written informed consent was ob-
tained from all participants. A total of
1,059 eligible participants (559 over-
weight/obese and 500 normal-weight)
were successfully recruited.
Of these individuals, 960 (90.7%)
completed a dual-energy X-ray absorpti-
ometry (DEXA) scan. Baseline character-
istics (BMI, waist circumference, family
history of chronic diseases, smoking, al-
cohol drinking, and educational attain-
ment) were similar between those with
and without DEXA scans. However, indi-
viduals who did not participate in the
DEXA scan were younger (43.0 vs. 46.2
years; P  0.001) and tended to be male
(57.6 vs. 36.7%, P  0.001) compared
with those who had the scan.
Data collection
Home interviews were conducted by
trained physicians or public health work-
ers from the local Centers for Disease
Control and Prevention and community
clinics.Informationondemographicvari-
ables, health status, and behavior was
collected using a standardized question-
naire.Smokingwasdeﬁnedasnever,cur-
rent, and former. Alcohol drinking was
deﬁned as “yes” or “no.” Physical activity
data were collected by using the Interna-
tional Physical Activity Questionnaire
(short last 7-day format, http://www.
ipaq.ki.se/scoring.pdf), and the level for
eachindividualwascalculatedasasumof
MET-minute/week score and then classi-
ﬁed as low and high by sex-speciﬁc total
METmedian.Educationalattainmentwas
categorized into three groups (0 to 9, 10
to 12, and 13 years of education). Fam-
ilyhistoryofchronicdiseaseswaspositive
if a parent or sibling had coronary heart
disease, stroke, or type 2 diabetes.
After a home interview, all partici-
pants had a physical examination after
overnightfasting.Bodyweightandheight
were measured to the nearest 0.1 kg and
0.1cm,respectively,withtheparticipants
in light indoor clothing without shoes.
BMIwascalculatedasweightinkilograms
divided by the square of height in meters.
Waist circumference was obtained at the
midpoint between the lowest rib and the
iliac crest to the nearest 0.1 cm, after in-
halation and exhalation. Blood pressure
was measured by using an electronic
blood pressure monitor (Omron HEM-
705CP; OMRON Healthcare, Vernon
Hills, IL) on the right arm of the partici-
pantinacomfortablesittingpositionafter
at least a 5-min rest. Three measurements
were taken and the mean of the last two
measurements was used for the analyses.
Whole-body densitometry was con-
ducted with the participant in light cloth-
ing and without carrying any metal
objects by using a Hologic DXA (QDR-
4500; Hologic, Waltham, MA).
Laboratory methods
Fasting peripheral venous EDTA blood
sampleswerecollectedandcentrifugedat
4°C and 3,000 rpm for 15 min. After be-
ing frozen, the samples were shipped in
dry ice to the Institute for Nutritional Sci-
ences and stored at 80°C until analyses.
Total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides, glucose, aspar-
tate aminotransferase (AST), alanine
aminotransferase (ALT), and -glutamyl-
transferase (GGT) were measured enzy-
matically on an automatic analyzer
(Hitachi 7080, Tokyo, Japan) with re-
agentspurchasedfromWakoPureChem-
ical Industries (Osaka, Japan). Plasma
high-sensitivity (hs) C-reactive protein
(CRP) was measured by a particle-
enhanced immunoturbidimetric assay
(Roche Diagnostics, Indianapolis, IN).
A1C was quantiﬁed from resolved eryth-
rocytes with an automated immunoassay
(Roche Diagnostics). Insulin was mea-
sured with a completely homologous ra-
dioimmunoassay (Linco Research, St.
Charles, MO), which had 0.2% cross-
reactivity with proinsulin. The insulin re-
sistance index (homeostasis model
assessment of insulin resistance [HOMA-
IR]) was calculated using updated ho-
meostasis model assessment methods
(http://www.dtu.ox.ac.uk/).
Plasma LBP levels were determined
by a sandwich ELISA (USCN Life Science
& Technology, Missouri City, TX).
Plasma samples were diluted at least 200
times and assayed according to the man-
ufacturer’s instructions. The assay has a
sensitivity of 0.2 ng/ml and a measurable
concentration range of 0.78–50 ng/ml.
Theintra-assayandinterassaycoefﬁcients
of variation were 5 and 10%, respec-
tively. Enzyme immunoassays were used
tomeasureplasmainterleukin(IL)-6,lep-
tin (R&D Systems, Minneapolis, MN),
and high-molecular-weight (HMW)-
adiponectin (Millipore, St. Charles, MO).
The interassay coefﬁcients of variation
were 9.6 and 6.5% for IL-6 at 0.49 and
5.65 pg/ml, 5.4 and 3.5% for leptin at
65.7and581pg/ml,and8.1and3.8%for
HMW-adiponectin at 21.23 and 61.50
ng/ml, respectively. Hepatitis B surface
antigen (HBsAg) was detected by a Murex
HBsAg ELISA kit (Murex Biotech, Dart-
ford, Kent, U.K.).
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Metabolic syndrome was deﬁned accord-
ing to the updated National Cholesterol
Education Program Adult Treatment
Panel III criteria for Asian-Americans
(16),includingatleastthreeofthefollow-
ing components: 1) waist circumferences
90 cm in men or 80 cm in women, 2)
triglycerides 1.7 mmol/l, 3) HDL cho-
lesterol 1.03 mmol/l in men or 1.30
mmol/l in women, 4) blood pressure
130/85mmHgorcurrentuseofantihy-
pertensive medications, and 5) fasting
plasma glucose 5.6 mmol/l. Type 2 di-
abetes was deﬁned as fasting plasma glu-
cose7.0mmol/lor2-hpostloadplasma
glucose11.1mmol/lduringanoralglu-
cose tolerance test. The selection proce-
dure for the oral glucose tolerance test is
described in supplementary Fig. A1
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0340/DC1). Elevated hepatic
enzymes were deﬁned as the highest
quartilesofoneormorehepaticenzymes:
AST 30 IU/l, ALT 33 IU/l, or GGT
42 IU/l.
Statistical analyses
Log transformations were performed for
LBP, triglycerides, insulin, HOMA-IR, in-
ﬂammatory makers, adipokines, and he-
patic enzymes to approximate normality.
ANCOVA for continuous variables and
logistic regression models for categorical
variableswereappliedforthecomparison
across obesity status. Multiple compari-
son corrections were performed using the
Benjamini and Hochberg procedure (17).
Partial Spearman correlation coefﬁcients
between LBP and various parameters
were calculated by adjustment for age,
sex, and BMI. Individuals with presum-
ably acute inﬂammation (hs-CRP 10
mg/l)wereexcluded(n18,1.7%),leav-
ing 1,041 subjects in the analysis. Of
these, 942 subjects completed a DEXA
scan.
Participants were classiﬁed into four
groups according to their LBP quartiles in
thewholesample.Multivariatelogisticre-
gressionmodelswereusedtoestimatethe
odds ratios (ORs) for metabolic syn-
drome, type 2 diabetes, and insulin resis-
tance. Potential confounding variables
include age, sex, lifestyle factors, educa-
tion level, family history of chronic dis-
eases, and BMI (or total body fat). In
addition, we adjusted for inﬂammatory
markers, adipokines, and elevated he-
paticenzymes.Datamanagementandsta-
tistical analyses were performed using
Stata9.2(StataCorp,CollegeStation,TX).
Statistical tests were two-sided and P 
0.05 was considered statistically
signiﬁcant.
RESULTS
General characteristics
The prevalence of metabolic syndrome
and newly deﬁned type 2 diabetes was
42.0% (n  445) and 13.8% (n  146),
respectively. The mean BMI values were
28.0  2.7 kg/m
2 in overweight/obese
subjectsand21.01.4kg/m
2innormal-
weight subjects (P  0.001) (Table 1).
Compared with normal-weight sub-
jects, overweight/obese individuals were
more likely to have lower educational at-
tainment and higher prevalence of meta-
bolic syndrome and type 2 diabetes (all
P  0.01) (Table 1). They also had higher
values for waist circumference, blood
pressure, glucose, A1C, insulin, HOMA-
IR, total cholesterol, LDL cholesterol, and
triglycerides and lower HDL cholesterol
concentration (all P  0.05). Meanwhile,
they exhibited higher levels of total body
fat mass/percentage and trunk fat mass
(all P  0.001), hepatic enzymes (AST,
ALT, and GGT), inﬂammatory markers
(hs-CRP and IL-6) and leptin, accompa-
nied by lower concentrations of HMW-
adiponectin (all P  0.001). Importantly,
plasma LBP levels were signiﬁcantly
higher in overweight/obese participants
than in normal-weight participants (geo-
metricmean27.6[95%CI25.2–30.3]vs.
10.0 [9.1–11.1] g/ml; P  0.001). In
addition, LBP levels were higher in sub-
jectswithimpairedfastingglucosethanin
those with normal fasting glucose (16.7
[15.0–18.6] vs. 13.8 [12.2–15.6] g/ml;
P  0.041) and higher in subjects with
impaired glucose tolerance than in those
with normal glucose tolerance (31.2
[24.3–40.1] vs. 14.4 [12.8–16.3] g/ml;
P  0.001), after adjustment for age and
sex.
Correlation between LBP
concentrations and metabolic
parameters
LBP was positively correlated with BMI,
waist circumference (all P  0.001) (sup-
plementary Table A1, available in an on-
line appendix), blood pressure, total
cholesterol, LDL cholesterol, triglycer-
ides, glucose, insulin, HOMA-IR, hepatic
enzymes,andleptinandnegativelycorre-
lated with HDL cholesterol and HMW-
adiponectin (all P  0.05, data not
shown), after adjustment for age and sex.
Plasma LBP was also highly correlated
with inﬂammatory markers (hs-CRP r 
0.93 and IL-6 r  0.50, both P  0.001)
after adjustment for age and sex. These
correlation coefﬁcients were attenuated
but remained statistically signiﬁcant after
further adjustment for BMI (supplemen-
tary Table A1). When the analyses were
stratiﬁedbyobesitystatus,signiﬁcantcor-
relations with the metabolic traits were
more pronounced among overweight/
obese subjects than among normal-
weight individuals. In addition, LBP was
strongly correlated with total body fat
mass/percentage and trunk fat mass in
sex-stratiﬁed correlation models (all P 
0.001) (data not show).
Associations of LBP concentrations
with metabolic syndrome, type 2
diabetes, and insulin resistance
The risk for metabolic syndrome in the
whole study sample increased progres-
sively across the LBP quartiles (Ptrend 
0.001) (Table 2) and those in the highest
LBP quartile had an OR of 3.54 (95% CI
2.05–6.09) compared with those in the
lowest quartile (model 2), after adjust-
ment for age, sex, lifestyle factors, family
historyofchronicdiseases,andBMI.Sim-
ilartrendswerealsoobservedforthemet-
abolic syndrome components. Further
adjustment for inﬂammatory markers
(model 3) abolished the signiﬁcant asso-
ciationsformetabolicsyndromeandmost
ofitscomponentsexceptforhypertriglyc-
eridemia and low HDL cholesterol.
For those with newly deﬁned type 2
diabetes, the OR in the highest quartile
was5.53(95%CI2.64–11.59)compared
withthatinthelowestLBPquartile(Ptrend
 0.001) in the multivariable model (Ta-
ble 2, model 2). A positive association be-
tween LBP and insulin resistance,
represented by the highest quartile of
HOMA-IR, was also observed in nondia-
betic participants (OR 1.90 [95% CI
1.10–3.28]). The ORs for diabetes and
insulinresistancewereslightlyattenuated
but remained statistically signiﬁcant after
further adjustment for hs-CRP and IL-6
(model 3).
The associations between LBP and
metabolic disorders were not attenuated
by additionally controlling for HMW-
adiponectin, leptin, and elevated hepatic
enzymes (as categorical or continuous
variables) in model 2 (data not shown).
Replacing BMI with total body fat mass in
the multiple regression models also did
not materially change the magnitude of
the associations. The results remained
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subjects (n  91, 8.7%) or subjects with
18.0  BMI 18.5 kg/m
2 (n  14, 1.3%)
(data not shown).
Wefurtherconductedjointclassiﬁca-
tion analyses to examine whether obesity,
trunk fat mass, HMW-adiponectin, and
elevatedhepaticenzymesmodiﬁedtheas-
sociations of LBP with metabolic syn-
drome and type 2 diabetes (Fig. 1). No
signiﬁcant interactions were observed be-
tween LBP and these factors (P  0.05 for
all interaction tests).
CONCLUSIONS — Ourdatashowed
signiﬁcant associations between elevated
LBP concentrations and the risk for met-
abolic syndrome, insulin resistance, and
type 2 diabetes independent of conven-
tionalcardiovascularriskfactorsinanap-
parently healthy Chinese population.
Further adjustment for inﬂammatory fac-
tors, but not for adipokines and elevated
hepaticenzymes,substantiallyattenuated
the associations for metabolic syndrome
and most of its components, suggesting
that chronic inﬂammation may mediate
the effects of innate immune response in-
duced by LPS-LBP.
In a previous human study, Ghanim
et al. (18) reported that increased plasma
LPS and LBP and also expression of Toll-
like receptors and suppressor of cytokine
signaling-3 in mononuclear cells (MNCs)
could be induced by consuming a meal
with a high-fat, high-carbohydrate con-
tent, but not with isocaloric fruit and
ﬁber, implying a potential role of the
LPS-LBP pathway in postprandial inﬂam-
mation and related metabolic disorders.
Inaddition,positivecorrelationsbetween
LBP and metabolic traits such as BMI, di-
astolicbloodpressure,fastingglucose,in-
sulin, and triglycerides were observed in
60 men with glucose intolerance (13).
Moreover, a higher LBP level was associ-
ated with increased prevalence of coro-
nary artery disease independent of
established cardiovascular risk factors in
247 male patients (12). With a relatively
large sample size of apparently healthy
men and women, our study provides
more convincing evidence about the rela-
tionship between LBP and metabolic
abnormalities.
In recent years, the effects of micro-
biota on health have attracted increasing
attention, and low-grade endotoxemia or
LPS was found to link to various meta-
bolicconsequences.However,moststud-
ies have been performed in mice and few
in human populations. Studies in mice
demonstrated that two- to threefold in-
creased circulating LPS induced by a
high-fat diet or LPS infusion led to in-
creased levels of fasting glucose and insu-
lin and body weight gain (4,5). The
occurrences of a metabolic response
could be counteracted by a CD14 mutant
(5) or improved by changing gut micro-
biota (4). In humans, a high LPS concen-
trationwasfoundinindividualswithtype
Table 1—Characteristics of participants according to obese status
Normal weight
(18.0  BMI 24.0 kg/m
2)
Overweight/obesity
(BMI 24.0 kg/m
2) P value*
n 500 559
Age (years)† 45.8  5.5 46.0  5.4 0.604
BMI (kg/m
2) 21.0  1.4 28.0  2.7 0.001‡
Men† 175 (35.0) 234 (41.9) 0.022‡
Physical inactivity 249 (49.8) 281 (50.3) 0.869
Education levels 0.002‡
0–9 years 114 (22.8) 175 (31.3)
10–12 years 273 (54.6) 281 (50.3)
12 years 113 (22.6) 103 (18.4)
Current smoker (yes) 117 (23.4) 158 (28.3) 0.767
Alcohol drinker (yes) 183 (36.6) 204 (36.5) 0.245
Family history of chronic
diseases 200 (40.0) 222 (39.7) 0.939
Newly deﬁned type 2 diabetes 36 (7.2) 110 (19.7) 0.001‡
Metabolic syndrome 51 (10.2) 394 (70.5) 0.001‡
Waist circumference (cm) 75.9  6.1 93.2  8.2 0.001‡
Systolic blood pressure
(mmHg) 118.4  15.3 130.9  17.6 0.001‡
Diastolic blood pressure
(mmHg) 74.7  9.8 84.0  11.6 0.001‡
Glucose (mmol/l) 5.81  1.13 6.30  1.54 0.001‡
A1C (%) 5.58  0.62 5.79  0.78 0.001‡
Insulin (U/ml) 7.3 (7.07.7) 11.3 (10.911.8) 0.001‡
HOMA-IR 0.85 (0.820.89) 1.33 (1.271.38) 0.001‡
Total cholesterol (mmol/l) 5.16  1.14 5.33  1.18 0.014‡
LDL cholesterol (mmol/l) 3.14  0.93 3.41  0.99 0.001‡
HDL cholesterol (mmol/l) 1.53  0.44 1.23  0.34 0.001‡
Triglycerides (mmol/l) 1.01 (0.961.06) 1.61 (1.531.69) 0.001‡
DEXA scan 456 (91.2) 504 (90.2) 0.697
Total body fat mass (kg)
(n  960)
Men 11.8  3.3 20.7  4.3 0.001‡
Women 15.7  2.8 25.7  5.1 0.001‡
Total body fat (%) (n  960)
Men 19.0  4.3 25.6  3.4 0.001‡
Women 29.4  3.8 36.1  3.6 0.001‡
Trunk fat mass (kg) (n  960)
Men 6.3  2.1 12.1  2.7 0.001‡
Women 7.7  1.8 13.7  3.0 0.001‡
HBsAg carriage 44 (8.8) 50 (8.9) 0.916
Elevated hepatic enzymes 141 (28.2) 294 (52.6) 0.001‡
AST (IU/l) 23.6 (22.9–24.3) 26.3 (25.4–27.2) 0.001‡
ALT (IU/l) 19.1 (18.2–20.0) 27.8 (26.5–29.2) 0.001‡
GGT (IU/l) 22.5 (21.3–23.8) 33.1 (31.2–35.0) 0.001‡
hs-CRP (mg/l) 0.61 (0.57–0.66) 1.38 (1.28–1.49) 0.001‡
IL-6 (pg/ml) 1.19 (1.13–1.26) 1.67 (1.59–1.76) 0.001‡
HMW-adiponectin (g/ml) 3.16 (2.93–3.41) 1.88 (1.73–2.04) 0.001‡
Leptin (ng/ml) 3.99 (3.70–4.31) 8.94 (8.40–9.51) 0.001‡
LBP (g/ml) 10.0 (9.1–11.1) 27.6 (25.2–30.3) 0.001‡
Data are arithmetic mean  SD, n (%), or geometric mean (95% CI). n  1,059. Percentages may not sum
to 100 because of rounding. *P value was calculated after adjustment for age and sex; P value for body fat
comparison was not adjusted for sex. †Data not adjusted for itself. ‡Benjamini and Hochberg–corrected
statistical signiﬁcance (17).
Marker of endotoxemia and metabolic disorders
1928 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.org2 diabetes (6). The administration of ros-
iglitazone, a hypoglycemic agent with a
potential anti-inﬂammatory effect (19),
couldreduceLPSlevels(6).However,the
shorthalf-lifeofLPS(8)andthedisadvan-
tages associated with its assay (9) have
limited its potential applications in rou-
tine clinical settings and large-scale stud-
ies. Having a relatively long half-life and
reliable measurements, LBP might serve
as a marker reﬂecting an “effective” LPS
level and innate immune response trig-
geredbyLPS(11,12).Therefore,circulat-
ing LBP levels can be considered a
promising early biomarker and interven-
tion target for inﬂammatory conditions.
We observed a stronger correlation
between LBP and inﬂammatory markers
than that between LBP and adipokines af-
teradjustmentforBMI.Moreover,adjust-
ingforhs-CRPandIL-6almosteliminated
the associations of LBP with metabolic
syndrome and most of its traits (Table 2,
model 3), whereas controlling for HMW-
adiponectin and leptin had little impact
on the associations. A potential mecha-
nism is that LPS-LBP–triggered immune
response activates the nuclear factor-B
pathway, stimulates formation of IL-6,
IL-1,andtumornecrosisfactor-	(7),and
upregulates CRP synthesis in hepato-
cytes. However, it is noteworthy that low
plasma HMW-adiponectin contributed
additional risk for metabolic syndrome
and type 2 diabetes under the high LBP
condition (Fig. 1E and F). In fact, existing
data showed that LPS increased plasma
leptin levels and downregulated adi-
ponectin receptor mRNA in healthy vol-
unteers (20).
We also examined whether adjust-
ment for hepatic enzymes altered the as-
sociations, because LBP is synthesized in
liver and LPS could cause hepatocyte
damage by inducing upregulation of tu-
mor necrosis factor-	 expression in
Kupffer cells (7). Previous prospective
studies also suggested that elevated he-
Table 2—ORs (95% CI) for metabolic syndrome, type 2 diabetes, and insulin resistance according to quartiles of LBP
Quartile of LBP
Ptrend
Q1 (LBP 6.5
g/ml)
Q2 (6.5  LBP
15.8 g/ml)
Q3 (15.8  LBP
42.0 g/ml)
Q4 (LBP 42.0
g/ml)
Metabolic syndrome (n  1,041) 35/260 91/260 132/261 176/260
Model 1 1 3.45 (2.22–5.37) 6.25 (4.05–9.65) 12.90 (8.28–20.10) 0.001
Model 2 1 2.78 (1.64–4.72) 3.04 (1.81–5.12) 3.54 (2.05–6.09) 0.001
Model 3 1 2.56 (1.50–4.38) 2.38 (1.36–4.15) 1.80 (0.84–3.88) 0.053
Central obesity 59/260 110/260 164/261 204/260
Model 1 1 2.50 (1.71–3.66) 5.92 (4.01–8.72) 12.80 (8.42–19.47) 0.001
Model 2 1 1.64 (0.85–3.16) 2.54 (1.30–4.97) 2.53 (1.18–5.43) 0.005
Model 3 1 1.49 (0.77–2.90) 1.88 (0.90–3.92) 1.09 (0.35–3.35) 0.304
Elevated blood pressure 66/260 89/260 119/261 157/260
Model 1 1 1.51 (1.02–2.23) 2.24 (1.53–3.28) 4.19 (2.85–6.15) 0.001
Model 2 1 1.16 (0.76–1.76) 1.32 (0.87–2.00) 1.73 (1.11–2.69) 0.013
Model 3 1 1.09 (0.71–1.67) 1.08 (0.69–1.68) 0.94 (0.50–1.75) 0.982
Hypertriglyceridemia 25/260 70/260 102/261 130/260
Model 1 1 3.61 (2.18–5.99) 5.82 (3.56–9.52) 9.34 (5.72–15.25) 0.001
Model 2 1 3.11 (1.85–5.24) 4.05 (2.43–6.76) 4.98 (2.94–8.43) 0.001
Model 3 1 3.04 (1.80–5.12) 3.77 (2.23–6.38) 4.10 (2.14–7.85) 0.001
Low HDL cholesterol 65/260 82/260 116/261 118/260
Model 1 1 1.43 (0.97–2.11) 2.64 (1.81–3.86) 2.77 (1.89–4.04) 0.001
Model 2 1 1.17 (0.78–1.75) 1.72 (1.15–2.58) 1.39 (0.90–2.15) 0.056
Model 3 1 1.18 (0.78–1.76) 1.76 (1.15–2.68) 1.54 (0.87–2.72) 0.027
Hyperglycemia 140/260 157/260 174/261 188/260
Model 1 1 1.28 (0.90–1.82) 1.64 (1.14–2.35) 2.14 (1.48–3.09) 0.001
Model 2 1 1.18 (0.82–1.69) 1.34 (0.92–1.97) 1.49 (0.99–2.27) 0.047
Model 3 1 1.08 (0.75–1.56) 1.00 (0.66–1.52) 0.60 (0.32–1.13) 0.382
Type 2 diabetes (n  1,041) 10/260 22/260 43/261 67/260
Model 1 1 2.29 (1.06–4.95) 4.71 (2.30–9.61) 8.30 (4.15–16.59) 0.001
Model 2 1 1.99 (0.91–4.33) 3.53 (1.69–7.37) 5.53 (2.64–11.59) 0.001
Model 3 1 1.93 (0.88–4.21) 3.06 (1.45–6.46) 3.23 (1.38–7.58) 0.003
Q1 (LBP 5.9
g/ml)
Q2 (5.9  LBP
12.7 g/ml)
Q3 (12.7  LBP
37.8 g/ml)
Q4 (LBP 37.8
g/ml) Ptrend
Insulin resistance (n  899) 27/224 38/225 72/225 87/225
Model 1 1 1.49 (0.87–2.54) 3.48 (2.13–5.70) 4.64 (2.85–7.55) 0.001
Model 2 1 1.12 (0.64–1.98) 1.95 (1.14–3.32) 1.90 (1.10–3.28) 0.005
Model 3 1 1.14 (0.64–2.01) 1.97 (1.14–3.41) 1.95 (0.97–3.92) 0.014
Model 1: adjusted for age and sex. Model 2: further adjusted for smoking (current, yes or no), alcohol drinking (yes or no), physical activity (low or high by the
sex-speciﬁc MET/week median), education (0–9, 10–12, and 13 years), family history of chronic diseases (yes or no), and BMI. Model 3: further adjusted for
hsCRP and IL-6.
Sun and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 1929Figure 1—ORs for metabolic disorders according to joint classiﬁcation of LBP and obesity status (A and B), trunk fat (sex and obesity-stratiﬁed
tertile [T], C and D), HMW-adiponectin (E and F), and hepatic enzymes (G and H). A–D: Modiﬁed metabolic syndrome was deﬁned as having two
or more components of metabolic syndrome without central obesity. Adjusted for age, sex, smoking, alcohol drinking, physical activity, education,
and family history of chronic diseases. E–H: Adjusted for age, sex, smoking, alcohol drinking, physical activity, education, family history of chronic
diseases, and BMI.
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syndrome and type 2 diabetes (21). How-
ever, no material change was observed
when we controlled for elevated hepatic
enzymes or excluded individuals having
hepatitis B infection. Collectively, our
ﬁndings indicate that the inﬂammatory
cascade initiated by LPS-LBP triggered an
innate immune response, which is a ma-
jor mechanism linking LBP to the patho-
genesis of metabolic disorders.
Interestingly, unlike the case for met-
abolic syndrome risk, controlling for in-
ﬂammatory markers in current study did
not alter the signiﬁcant associations of
LBPwithdyslipidemia,insulinresistance,
and type 2 diabetes (Table 2). The minor
effect of inﬂammation on the association
between LBP and dyslipidemia might be
explained by a sequence identity shared
between LBP and lipid transfer proteins
that could modify lipid homeostasis dur-
ing subclinical endotoxemia (22). Previ-
ous studies demonstrated that
hyperinsulinemia might affect immune
competence, including functions of neu-
trophils (13) and hepatic Kupffer cells
(23), which subsequently inﬂuenced LPS
clearance and LBP synthesis. Neverthe-
less, endotoxemia might induce insulin
resistance, whereas CD14 mutant mice
showed hypersensitivity to insulin (5).
MNCs were also suggested to be a target
of insulin action and involved in the in-
teraction between inﬂammation and in-
sulin resistance (24). The increased
suppressor of cytokine signaling-3 ex-
pression in MNCs, accompanied by in-
creased LPS and LBP concentrations after
ahigh-fat,high-carbohydratemeal,might
also interfere with insulin signaling and
play a role in insulin resistance (18,24).
Our data suggested that LBP might exert
its inﬂuence directly on insulin action in
addition to stimulating a downstream
pathway generating inﬂammatory cyto-
kines. Moreover, the LBP gene was re-
cently found to be genetically susceptible
to type 2 diabetes in Japanese (25), which
may provide one possible reason that the
conventionally inﬂammatory cytokine
showed little impact on the association
between LBP and type 2 diabetes.
To our knowledge, this is the ﬁrst
study that systematically investigated the
associations of LBP concentrations with
the risk of obesity-related metabolic dis-
orders. Admittedly, the cross-sectional
nature of this study does not allow for a
causal inference. Nonetheless, we tried to
eliminatepotentialeffectsofacuteinﬂam-
mation and other potential confounders
by applying strict exclusion criteria and
alsoincludedarelativelylargesamplesize
with both sexes. Certainly, these results
should be examined prospectively and in
different populations to establish the
causal relationship between LBP, inﬂam-
mation, and metabolic outcomes.
OurstudyindicatesthatLBPissignif-
icantly associated with obesity-related
metabolicdisordersinapparentlyhealthy
Chinese. These ﬁndings indicate the role
of LPS-initiated innate immune mecha-
nisms in metabolic diseases. Future pro-
spective studies are needed to clarify
whether LBP predicts future risk of meta-
bolic disorders.
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